Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives Average Recommendation of “Moderate Buy” from Brokerages

Akero Therapeutics, Inc. (NASDAQ:AKRO) has been given an average rating of “Moderate Buy” by the eight analysts that are covering the stock, MarketBeat reports. One analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $46.83.

AKRO has been the subject of several research reports. Citigroup initiated coverage on Akero Therapeutics in a report on Monday, November 18th. They set a “buy” rating and a $65.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Akero Therapeutics in a report on Thursday.

Insider Buying and Selling

In related news, COO Jonathan Young sold 10,000 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $28.03, for a total value of $280,300.00. Following the transaction, the chief operating officer now owns 218,083 shares in the company, valued at approximately $6,112,866.49. This trade represents a 4.38 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Catriona Yale sold 4,515 shares of the firm’s stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $32.53, for a total value of $146,872.95. Following the completion of the transaction, the insider now owns 74,158 shares in the company, valued at $2,412,359.74. The trade was a 5.74 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 262,135 shares of company stock worth $8,223,000. Company insiders own 7.94% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Simplify Asset Management Inc. grew its position in Akero Therapeutics by 15.6% in the third quarter. Simplify Asset Management Inc. now owns 283,766 shares of the company’s stock valued at $8,141,000 after acquiring an additional 38,279 shares during the last quarter. Perceptive Advisors LLC grew its position in Akero Therapeutics by 8.1% in the second quarter. Perceptive Advisors LLC now owns 1,499,897 shares of the company’s stock valued at $35,188,000 after acquiring an additional 112,426 shares during the last quarter. FMR LLC grew its position in Akero Therapeutics by 732.1% in the third quarter. FMR LLC now owns 30,337 shares of the company’s stock valued at $870,000 after acquiring an additional 26,691 shares during the last quarter. Barclays PLC grew its position in Akero Therapeutics by 127.9% in the third quarter. Barclays PLC now owns 127,668 shares of the company’s stock valued at $3,662,000 after acquiring an additional 71,652 shares during the last quarter. Finally, Propel Bio Management LLC grew its position in Akero Therapeutics by 4.9% in the third quarter. Propel Bio Management LLC now owns 343,729 shares of the company’s stock valued at $9,862,000 after acquiring an additional 15,977 shares during the last quarter.

Akero Therapeutics Price Performance

Shares of AKRO opened at $25.14 on Monday. The stock has a market capitalization of $1.75 billion, a P/E ratio of -6.70 and a beta of -0.19. Akero Therapeutics has a twelve month low of $15.32 and a twelve month high of $37.00. The company has a 50 day moving average of $28.99 and a 200-day moving average of $27.99. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05.

Akero Therapeutics (NASDAQ:AKRO) last released its quarterly earnings data on Friday, November 8th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.15). As a group, equities research analysts forecast that Akero Therapeutics will post -3.96 EPS for the current fiscal year.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.